Earnings Summary

Iovance Biotherapeutics, Inc.’s revenue jumped 12385.07% since last year same period to $58.56Mn in the Q3 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 88.24% jump in its revenue since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit jumped 26.56% since last year same period to $-83.54Mn in the Q3 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 13.96% jump in its net profits since last 3-months.

Iovance Biotherapeutics, Inc.’s net profit margin jumped 99.41% since last year same period to -142.67% in the Q3 2024. On a quarterly growth basis, Iovance Biotherapeutics, Inc. has generated 54.3% jump in its net profit margins since last 3-months.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.42.

Iovance Biotherapeutics, Inc.’s earning per share (EPS) jumped 39.13% since last year same period to -0.28 in the Q3 2024. This indicates that the Iovance Biotherapeutics, Inc. has generated 39.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Iovance Biotherapeutics, Inc.’s return on assets (ROA) stands at -0.29.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Iovance Biotherapeutics, Inc.’s return on equity (ROE) stands at -0.57.